[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Le Bonheur Children's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":99},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100640782","a-clinical-study-used-to-estimate-central-venous-pressure-non-invasively-using-occlusion-pressure-100640782",false,"NCT07583680","A Clinical Study Used to Estimate Central Venous Pressure Non-invasively Using Occlusion Pressure","Non-Invasive Central Venous Pressure Estimation Using Occlusion Pressure: A Novel Approach for Accurate Hemodynamic Monitoring","CV-PRO","Inclusion Criteria:\n\n* Admitted to PICU or PCICU\n* Provided written informed consent\n* Continuous Central venous pressure monitoring transduced from a standard central venous catheter (not PICC line)\n\nExclusion Criteria:\n\n* Glenn and Fontan Patients\n* Heterotaxy Syndrome Patients\n* Inability to consent by guardian\u002Fcaretaker","ALL","17 Years",{"count":20,"type":21},30,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to collect different measurements using a method called peripheral venous pressure (PVP). PVP checks the pressure in the veins in the arms or legs. It can give doctors a good idea of how well the heart is working, similar to another method called central venous pressure (CVP), which doctors use in hospitals. In this study, the research team will measure PVP in people aged 0-17. The researcher hopes that this data will help doctors understand how PVP measurements relate to health outcomes, which could lead to better ways to diagnose and treat patients in the future.\n\nThe peripheral venous pressure (PVP) device will be used to non-invasively measure the pressure required to stop blood flow in the forearm, which will indirectly measure the PVP in the forearm. This device is composed of a pressure sensor and a Doppler flow detector that will be connected to a research laptop for data collection. This device will be placed on the forearm.\n\nIf you agree to be in this study, the study team will monitor the venous flow rate (the amount of blood moving through the veins over a certain period of time) using a Doppler Flow Detector while applying pressure to the vein with a pressure sensor. This will take place on the forearm.\n\nThe internal jugular vein will be identified and recorded using ultrasound imaging and Doppler sensor.\n\nThe forearm vein will be identified and marked using ultrasound imaging. Pressure will be applied for 15 seconds, and then stopped and repeated 4 times, making five sets of measurements.\n\nThe procedure may be repeated in 2-3 additional sessions during the hospital stay, if necessary.\n\nYour participation in this study will last approximately 30 minutes.\n\nThis procedure is for research only and will not affect your regular care. This will occur during your child's stay in the PCICU\u002FPICU. No additional study visits will be required.\n\nThe following procedures are being performed for research purposes only:\n\nCopying information such as your medical history from your medical record; Obtaining non-invasive peripheral venous pressure measurements.",[25,26],"Pediatric Congestive Heart Failure","Congestive Heart Failure",[28,29,30,31,25,26,32,33,34,35],"CHF","Pediatric CHF","Congenital Heart Disease","Pediatric Congenital Heart Disease","Heart Failure","CVP","Central Venous Pressure","CVP Monitor","NOT_YET_RECRUITING","2026-05-06",{"date":39,"type":40},"2026-05-13","ACTUAL",{"date":42,"type":21},"2026-07",{"date":44,"type":21},"2027-12",{"name":46,"class":47},"Le Bonheur Children's Hospital","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100579244","gastric-feeding-versus-transpyloric-feeding-in-infants-with-severe-bronchopulmonary-dysplasia-a-crossover-study-100579244","NCT06821776","Gastric Feeding Versus Transpyloric Feeding in Infants with Severe Bronchopulmonary Dysplasia, a Crossover Study","N-of-1 Trial Comparing Prolonged Gastric Feeding to Transpyloric Feeding in Infants with Severe Bronchopulmonary Dysplasia","Inclusion Criteria:\n\n* Patients born \\\u003C32 weeks' gestation\n* Currently admitted to the Le Bonheur NICU\n* Grad 2 or 3 BPD (positive pressure or intubated at 36 weeks PMA)\n* Signs of gastroesophageal reflux, chronic aspiration, or other feeding intolerance.\n\nExclusion Criteria:\n\n* Known gastrointestinal anomalies\n* Unable to tolerate ≥100mL\u002Fkg\u002Fday enteral feeding\n* Congenital anomalies likely to alter feeding techniques\n* Surgical feeding tube in place or expected within the next 8 weeks\n* Expected to remain hospitalized \\\u003C8 weeks","1 Month","1 Year",{"count":58,"type":21},25,"INTERVENTIONAL",[61],"NA","Hospitalized infants with severe bronchopulmonary dysplasia (BPD) and feeding intolerance will be randomized to 2 weeks of continuous gastric feeding or continuous transpyoloric feeding. Subjects will crossover after 2 weeks and receive 4 weeks of each feeding mode. Respiratory status will be assessed to determine the optimal feeding mode for each infant.",[64,65],"Bronchopulmonary Dysplasia","Feeding Intolerance",[67],"BPD","RECRUITING","2025-02-06",{"date":71,"type":40},"2025-02-12",{"date":73,"type":40},"2025-02-05",{"date":75,"type":21},"2030-02",{"name":46,"class":47},1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":56,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":77},"100378309","the-us-pda-registry-100378309","NCT04205877","The U.S. PDA Registry","The United States Patent Ductus Arteriosus Registry","Inclusion Criteria:\n\n1. Diagnosis of PDA.\n2. Clinical indication for transcatheter PDA closure (discretion of the physician).\n3. Weight \\\u003C2 kg at the time of device implant.\n\nExclusion Criteria:\n\n1. Weight \\\u003C700 gm or greater than or equal to 2 kg at the time of device implant.\n2. Age \\\u003C 3 days at the time of device implant.\n3. Pre-existing coarctation of the aorta.\n4. Pre-existing left pulmonary artery stenosis.\n5. Cardiac output that is dependent on right to left shunt through the PDA due to pulmonary hypertension.\n6. Intracardiac thrombus that interferes with device implant.\n7. Active infection requiring treatment at the time of impant.","3 Days",{"count":87,"type":21},5000,"The objective of this study is to demonstrate the continued safety and efficacy in a real-world setting of transcatheter device closure of the PDA in premature infants less than 2kg in weight at the time of device implant using the Amplatzer Piccolo Occluder device and other devices performed in the USA.",[90],"Ductus Arteriosus, Patent","2019-12-17",{"date":93,"type":40},"2019-12-20",{"date":95,"type":21},"2020-01-01",{"date":97,"type":21},"2031-12-01",{"name":46,"class":47},""]